CROI 2017 Program and Information

Program and Agenda

870 OPIOID SUBSTITUTION THERAPY AND INITIATION INTO INJECTION DRUG USE IN SAN DIEGO, CA Maria Luisa Mittal 1 , Devesh Vashishtha 1 , Xiaoying Sun 1 , Sonia Jain 1 , Richard S. Garfein 2 , Steffanie A. Strathdee 2 , Dan Werb 1 1 Univ of California San Diego, La Jolla, CA, USA, 2 Univ of California San Diego, San Diego, CA, USA 871 CHANGES IN PRESCRIPTION OPIOID, METH, AND COCAINE USE AMONGMSM IN20 US CITIES Brooke Hoots , Dita Broz, Lina Nerlander, Gabriela Paz-Bailey CDC, Atlanta, GA, USA 872 CHANGING PATTERN OF CRYSTALMETH USE IN BLACK&WHITE MSM,WASHINGTON, DC, 2008–2014 Irene Kuo 1 , Rudy Patrick 1 , Jenevieve Opoku 2 , Anthony Rawls 1 , Manya Magnus 1 , James Peterson 1 , Michael Kharfen 2 , Alan Greenberg 1 1 The George Washington Univ, Washington, DC, USA, 2 District of Columbia Dept of Hlth, Washington, DC, USA 873 INCREASINGMETHAMPHETAMINE USE AMONG NON-MSMWHO INJECT DRUGS IN KING COUNTY,WA Sara N. Glick 1 , Richard Burt 2 , Kim Kummer 1 , Joe Tinsley 2 , Caleb Banta- Green 1 , Matthew R. Golden 1 1 Univ of Washington, Seattle, WA, USA, 2 Pub Hlth - Seattle & King County, Seattle, WA, USA Themed Discussion Leader Karl Salzwedel , National Institutes of Health, Bethesda , MD, USA 433 NOVEL HIV PI WITHHIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING John O. Link , Darryl Kato, Michael Moore, AndrewMulato, Bernard Murray, Judy Mwangi, Nathan D. Shapiro, George Stepan, Yujin Wang, Zheng-Yu Yang Gilead Scis, Inc, Foster City, CA, USA 434 NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITORWITH IMPROVED RESISTANCE PROFILE Michael L. Mitchell , Mini Balakrishnan, Gediminas Brizgys, Ruby Cai, Eric Lansdon, Andrew Mulato, Mark Osier, Jianhong Wang, Helen Yu, Roman Sakowicz Gilead Scis, Inc, Foster City, CA, USA 435 MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION Jay Grobler , Carolyn McHale, Carol Freddo, Dan Dreyer, Li Sun, Marissa Vavrek, Sheila Breidinger, Kerry Fillgrove, Daria Hazuda, Ming-Tain Lai Merck & Co, Inc, West Point, PA, USA 436 GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI- RESISTANT HIV-1 Kirsten L. White , Nicolas Margot, Kirsten Stray, Helen Yu, George Stepan, Constantine Boojamra, Richard Mackman, Adrian Ray, Michael D. Miller, Tomas Cihlar Gilead Scis, Inc, Foster City, CA, USA Themed Discussion TD-15 I WANT A NEW DRUG Room 6 C 1:30 PM - 2:30 PM

Oral Sessions • Thursday

CROI 2017 68